We display that these inhibitors suppress SLC15A4-mediated endolysosomal TLR and NOD functions in many different human and mouse immune cells; we provide proof of their capacity to suppress inflammation in vivo As well as in medical configurations; and we provide insights into their system of action. Our results establish SLC15A4 being a druggable